|
|
![]() | ![]() | ![]() | ![]() |
| |||||||||
This excerpt taken from the ELN 20-F filed Feb 28, 2008. ACC-001
(Active Immunotherapeutic Conjugate) with Wyeth
ACC-001 is a novel beta amyloid immunoconjugate that leverages
the innovative conjugate technology that Wyeth has used in some
of its vaccine products. ACC-001 has also been granted fast
track designation by the FDA and is in Phase 2 clinical trials.
The ACC-001 approach is intended to induce a highly specific
antibody response to beta amyloid. The goal is to clear beta
amyloid while minimizing side effects such as inflammation of
the central nervous system.
|
| |||||||